Funding propels company’s proprietary platform consisting of Generative AI models and large-scale datasets purpose-built for designing and validating novel proteins, opening new frontiers in therapeutics and industrial applications
...
Expanding medical therapies based on Crispr gene-editing globally is “unrealistic” and the sector needs heavy investment to make the technology, which could transform treatment of diseases, accessible to all, ...
Launch fueled by syndicate of blue-chip investors co-led by Qiming Venture Partners USA and venBio Partners
Company’s proprietary end-to-end Encompass™ platform designs enhancement-targeting chimeric (ENTAC™) molecules
Founding team ...
New funding from the Chan Zuckerberg Initiative kickstarts CRISPR-enabled carbon removal research at the Innovative Genomics Institute
A new research program at the Innovative Genomics Institute (IGI), supported by a ...
LatchBio, a company accelerating the pace of scientific progress by enabling researchers to store and analyze data without touching code or cloud infrastructure, today announced a $28 million Series ...
Noyo, the leading API platform powering frictionless benefits, today announced that it has closed $45M in Series B financing. Norwest Venture Partners led the round, joined by Workday Ventures, ...
Concert Health, a leading behavioral health medical group, today announced the closing of its $42M Series B financing, led by Define Ventures with participation from existing investors Healthy Ventures, ...
Memora Health, the leading technology platform for virtual care delivery and complex care management, today announced the completion of a $40 million financing. Transformation Capital led the financing with ...
Proteins are the building blocks of the human body and have many critical roles. Since proteins are involved in multiple biological functions, they also play an important role in ...
Imagine a Star Trek-style body scanner that examines your body in such depth that it can produce a 3D computerised model to track your health. Jeff Kaditz didn’t just ...
Building a virtual model of an entire patient—cobbled together from data on vital signs, physical activity and other observations—has been a quest for device makers and drug developers alike, ...
Scribe Therapeutics is adding another $100 million to its coffers six months after unveiling a $20 million series A and a partnership with Biogen to work on gene editing ...
Scribe Therapeutics has completed an oversubscribed $100-million Series B financing, with aims to further develop its suite of custom gene-editing and delivery technologies based on molecular engineering, as well ...
Nearly a decade ago, when the first CRISPR companies started looking for capital, Behzad Aghazadeh passed.
Aghazadeh, one of biotech’s more opinionated investors, had invested in gene editing before, but ...
Concert Health, a leading behavioral health medical group, today announced the closing of its Series A funding round at $14 million led by Vertical Venture Partners with participation from ...
A new company called Scribe Therapeutics founded by two former members of CRISPR pioneer Jennifer Doudna’s UC Berkeley genetics lab (alongside Doudna herself) launched on Tuesday, debuting a platform designed ...
Three years ago, Jennifer Doudna gathered with two postdocs and a fellow biochemist around a circular table on the second floor of UC Berkeley’s Energy Biosciences building, where they ...
The genetic engineering start-up Synthego may have been founded by two brothers with no formal background in the field. But it has won support from investors who now include ...
